Neovacs SA
ALNEV
Company Profile
Business description
Neovacs SA is a biotechnology company focused on the development of "Kinoids", therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.
Contact
3-5, Impasse Reille
Paris75014
FRAT: +33 153109300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
22
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,624.90 | 6.60 | -0.08% |
| CAC 40 | 7,819.69 | 7.10 | -0.09% |
| DAX 40 | 24,177.39 | 49.10 | -0.20% |
| Dow JONES (US) | 42,343.65 | 740.58 | 1.78% |
| FTSE 100 | 8,763.74 | 14.31 | -0.16% |
| HKSE | 23,258.31 | 123.68 | -0.53% |
| NASDAQ | 19,199.16 | 461.96 | 2.47% |
| Nikkei 225 | 37,722.40 | 1.71 | -0.00% |
| NZX 50 Index | 12,362.26 | 220.07 | -1.75% |
| S&P 500 | 5,921.54 | 118.72 | 2.05% |
| S&P/ASX 200 | 8,396.90 | 10.70 | -0.13% |
| SSE Composite Index | 3,339.93 | 0.76 | -0.02% |